Getting Back to Health from Lymphoma with Newly Approved Drug
In a time where treatments for Hodgkin's lymphoma (HL) and systemic anaplastic large cell lymphoma (or more commonly known as ALCL) are rare, the FDA has added a new drug to the small arsenal of treatments by approving the drug called Adcetris. The last drug to ever be approved to treat patients suffering from HL was nearly 35 years ago and for ALCL, Adcetris is the first drug primarily meant for the disease. If the drug coverage of your Indiana health insurance plan covers Tier 1 drugs, it's likely that you're covered for this wonder drug. But keep in mind that being fairly new, it can be worth a lot of money when you don't have coverage.
According to the evaluation that the FDA did on the drug, both in single arm clinical trials for people suffering from HL and patients suffering from ALCL, Richard Pazdur, Office of the Oncology Drug Products director of FDA's Centre for Drug Evaluation & Research said that patients experienced significant response. When someone you love or if you are suffering from lymphoma (cancer of the lymphatic system), you're going to need the best treatment. However, quality care without breaking the bank means you need to have comprehensive insurance coverage.
Cancer cells works on the network of lymph nodes that are connected by various vessels which transport lymph fluid. The most common symptoms for lymphoma sufferers are weight loss, swollen lymph nodes, fatigue and fever. Chemotherapy is usually the treatment of choice but the downside includes serious damage to the bone marrow. On the other hand, autologous stem cell transplant only has few benefits while Adcetris can help with relief and healing.
Adetris works as antibody and drug. The antibody directs the drug to target lymphoma cells called CD30. When people who have progressed Hodgkin's lymphoma makes use of this drug, they can have significant positive response. In transplanting bone marrow stem cell, Adcetris works even more. For people who already had two chemotherapy treatments and not a candidate for transplant, Adcetris is also the main treatment.
Huge fraction of the participants in the clinical trial on both HL and ALCL had partial or full response to the drug in six months or 12 months respectively. With this development, the fight for cancer of the lymphoma and non Hodgkinýs lymphomas is already halfway won.
This health news update is brought to you by PMG Agency. When you are looking for insurance coverage in the state of Indiana, we have the leading plans from the top carriers. We'll shop for you, and help you save money. Get your free quote here.
